Andrea Navarria
Soborg, 2860, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Efficacy and Hypoglycemia Profile of Once-weekly Insulin Icodec vs Once-daily Comparators Across Demographic Subgroups.
Journal: The Journal of clinical endocrinology and metabolism
Published: December 02, 2024
Pharmacological characteristics of once-weekly insulin icodec in Japanese individuals with type 1 diabetes.
Journal: Journal of diabetes investigation
Published: October 07, 2024
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: September 09, 2021
Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.
Journal: Cell reports. Medicine
Published: April 20, 2021
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials.
Journal: Clinical pharmacokinetics
Published: April 12, 2021
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Journal: The lancet. Diabetes & endocrinology
Published: December 10, 2019
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
Journal: The lancet. Diabetes & endocrinology
Published: November 26, 2019
Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials.
Journal: The Journal of clinical endocrinology and metabolism
Published: June 05, 2019
A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.
Journal: Expert opinion on drug metabolism & toxicology
Published: June 14, 2018
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Journal: The lancet. Diabetes & endocrinology
Published: November 28, 2017
Showing 1-10 of 10
Last Updated: 09/26/2026